Literature DB >> 11044106

Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles.

U B Balasuriya1, H W Heidner, J F Hedges, J C Williams, N L Davis, R E Johnston, N J MacLachlan.   

Abstract

RNA replicon particles derived from a vaccine strain of Venezuelan equine encephalitis virus (VEE) were used as a vector for expression of the major envelope proteins (G(L) and M) of equine arteritis virus (EAV), both individually and in heterodimer form (G(L)/M). Open reading frame 5 (ORF5) encodes the G(L) protein, which expresses the known neutralizing determinants of EAV (U. B. R. Balasuriya, J. F. Patton, P. V. Rossitto, P. J. Timoney, W. H. McCollum, and N. J. MacLachlan, Virology 232:114-128, 1997). ORF5 and ORF6 (which encodes the M protein) of EAV were cloned into two different VEE replicon vectors that contained either one or two 26S subgenomic mRNA promoters. These replicon RNAs were packaged into VEE replicon particles by VEE capsid protein and glycoproteins supplied in trans in cells that were coelectroporated with replicon and helper RNAs. The immunogenicity of individual replicon particle preparations (pVR21-G(L), pVR21-M, and pVR100-G(L)/M) in BALB/c mice was determined. All mice developed antibodies against the recombinant proteins with which they were immunized, but only the mice inoculated with replicon particles expressing the G(L)/M heterodimer developed antibodies that neutralize EAV. The data further confirmed that authentic posttranslational modification and conformational maturation of the recombinant G(L) protein occur only in the presence of the M protein and that this interaction is necessary for induction of neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11044106      PMCID: PMC110936          DOI: 10.1128/jvi.74.22.10623-10630.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  39 in total

1.  Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles.

Authors:  N L Davis; I J Caley; K W Brown; M R Betts; D M Irlbeck; K M McGrath; M J Connell; D C Montefiori; J A Frelinger; R Swanstrom; P R Johnson; R E Johnston
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

2.  Identification by anti-idiotype antibodies of an intracellular membrane protein that recognizes a mammalian endoplasmic reticulum retention signal.

Authors:  D Vaux; J Tooze; S Fuller
Journal:  Nature       Date:  1990-06-07       Impact factor: 49.962

3.  Neutralization determinants of laboratory strains and field isolates of equine arteritis virus: identification of four neutralization sites in the amino-terminal ectodomain of the G(L) envelope glycoprotein.

Authors:  U B Balasuriya; J F Patton; P V Rossitto; P J Timoney; W H McCollum; N J MacLachlan
Journal:  Virology       Date:  1997-05-26       Impact factor: 3.616

Review 4.  Assembly of asparagine-linked oligosaccharides.

Authors:  R Kornfeld; S Kornfeld
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

5.  Intracellular transport of recombinant coronavirus spike proteins: implications for virus assembly.

Authors:  H Vennema; L Heijnen; A Zijderveld; M C Horzinek; W J Spaan
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

6.  Responses of horses vaccinated with avirulent modified-live equine arteritis virus propagated in the E. Derm (NBL-6) cell line to nasal inoculation with virulent virus.

Authors:  W H McCollum
Journal:  Am J Vet Res       Date:  1986-09       Impact factor: 1.156

7.  Assembly of coronavirus spike protein into trimers and its role in epitope expression.

Authors:  B Delmas; H Laude
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

Review 8.  Folding and assembly of viral membrane proteins.

Authors:  R W Doms; R A Lamb; J K Rose; A Helenius
Journal:  Virology       Date:  1993-04       Impact factor: 3.616

9.  Structural proteins of equine arteritis virus.

Authors:  A A de Vries; E D Chirnside; M C Horzinek; P J Rottier
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

10.  Equine arteritis virus is not a togavirus but belongs to the coronaviruslike superfamily.

Authors:  J A den Boon; E J Snijder; E D Chirnside; A A de Vries; M C Horzinek; W J Spaan
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

View more
  19 in total

1.  Alphavirus replicon approach to promoterless analysis of IRES elements.

Authors:  K I Kamrud; M Custer; J M Dudek; G Owens; K D Alterson; J S Lee; J L Groebner; J F Smith
Journal:  Virology       Date:  2006-12-06       Impact factor: 3.616

2.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

3.  Structure and immunogenicity of alternative forms of the simian immunodeficiency virus gag protein expressed using Venezuelan equine encephalitis virus replicon particles.

Authors:  Chad Cecil; Ande West; Martha Collier; Christy Jurgens; Victoria Madden; Alan Whitmore; Robert Johnston; Dominic T Moore; Ronald Swanstrom; Nancy L Davis
Journal:  Virology       Date:  2007-02-01       Impact factor: 3.616

Review 4.  Equine viral arteritis.

Authors:  N James MacLachlan; Udeni B Balasuriya
Journal:  Adv Exp Med Biol       Date:  2006       Impact factor: 2.622

5.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

6.  Generation of a candidate live marker vaccine for equine arteritis virus by deletion of the major virus neutralization domain.

Authors:  Javier Castillo-Olivares; Roeland Wieringa; Tamás Bakonyi; Antoine A F de Vries; Nick J Davis-Poynter; Peter J M Rottier
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

7.  Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults.

Authors:  M Wecker; P Gilbert; N Russell; J Hural; M Allen; M Pensiero; J Chulay; Ya-Lin Chiu; S S Abdool Karim; D S Burke
Journal:  Clin Vaccine Immunol       Date:  2012-08-22

8.  Development of a fluorescent-microsphere immunoassay for detection of antibodies specific to equine arteritis virus and comparison with the virus neutralization test.

Authors:  Yun Young Go; Susan J Wong; Adam J Branscum; Valerie L Demarest; Kathleen M Shuck; Mary L Vickers; Jianqiang Zhang; William H McCollum; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

9.  Vaccination of mice with gonococcal TbpB expressed in vivo from Venezuelan equine encephalitis viral replicon particles.

Authors:  Christopher E Thomas; Weiyan Zhu; Cornelius N Van Dam; Nancy L Davis; Robert E Johnston; P Frederick Sparling
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

10.  Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling.

Authors:  Matthew Frieman; Kiira Ratia; Robert E Johnston; Andrew D Mesecar; Ralph S Baric
Journal:  J Virol       Date:  2009-04-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.